UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 63

Sortiert nach

Continuous glucose monitoring‐based time‐in‐range using insulin glargine 300 units/ml versus insulin degludec 100 units/ml in type 1 diabetes: The head‐to‐head randomized controlled InRange trial

Diabetes, obesity & metabolism, 2023-02, Vol.25 (2), p.545-555

2023

Volltextzugriff (PDF)

AUTONOMY: The First Randomized Trial Comparing Two Patient-Driven Approaches to Initiate and Titrate Prandial Insulin Lispro in Type 2 Diabetes

Diabetes care, 2014-08, Vol.37 (8), p.2132-2140

2014

Volltextzugriff (PDF)

Response to comment on Edelman et al. AUTONOMY: the first randomized trial comparing two patient-driven approaches to initiate and titrate prandial insulin lispro in type 2 diabetes. Diabetes Care 2014;37:2132-2140

Diabetes care, 2014-12, Vol.37 (12), p.e263-e264

2014

Volltextzugriff (PDF)

CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes

Cardiovascular diabetology, 2023-03, Vol.22 (1), p.59-59, Article 59

2023

Volltextzugriff (PDF)

Double-Blind, Placebo-Controlled Trial Assessing Pramlintide Treatment in the Setting of Intensive Insulin Therapy in Type 1 Diabetes

Diabetes care, 2006-10, Vol.29 (10), p.2189-2195

2006

Volltextzugriff (PDF)

Insights into optimal basal insulin titration in type 2 diabetes: Results of a quantitative survey

Diabetes, obesity & metabolism, 2018-02, Vol.20 (2), p.301-308

2018

Volltextzugriff (PDF)

Temporal intra-individual variation of immunological biomarkers in type 1 diabetes patients: implications for future use in cross-sectional assessment

PloS one, 2013-11, Vol.8 (11), p.e79383-e79383

2013

Volltextzugriff (PDF)

Reference Guide for Integrating Continuous Glucose Monitoring Into Clinical Practice

The Diabetes educator, 2019-02, Vol.45 (1_suppl), p.3S-20S

2019

Volltextzugriff (PDF)

Detection of Hypoglycemia With the GlucoWatch Biographer

Diabetes care, 2001-05, Vol.24 (5), p.881-885

2001

Volltextzugriff (PDF)

Inadequate Insurance Coverage for Overweight/Obesity Management

The American journal of managed care, 2024-08, Vol.30 (The American Journal of Managed Care 8), p.365

Edelman, Steve

2024

Volltextzugriff (PDF)

C ontinuous glucose monitoring‐based time‐in‐range using insulin glargine 300 units/ ml versus insulin degludec 100 units/ ml in type 1 diabetes: The head‐to‐head randomized controlled InRange trial

Diabetes, obesity & metabolism, 2023-02, Vol.25 (2), p.545-555

2023

Volltextzugriff (PDF)

Effects of Vitamin E on susceptibility of low-density lipoprotein and low-density lipoprotein subfractions to oxidation and on protein glycation in NIDDM

Diabetes care, 1995-06, Vol.18 (6), p.807

1995

Volltextzugriff (PDF)

CD8 T-cell reactivity to islet antigens is unique to type 1 while CD4 T-cell reactivity exists in both type 1 and type 2 diabetes

Journal of autoimmunity, 2014-05, Vol.50, p.77-82

2014

Volltextzugriff (PDF)

InRange: Comparison of the Second-Generation Basal Insulin Analogues Glargine 300 U/mL and Degludec 100 U/mL in Persons with Type 1 Diabetes Using Continuous Glucose Monitoring—Study Design

Diabetes therapy, 2020-04, Vol.11 (4), p.1017-1027

2020

Volltextzugriff (PDF)

Pramlintide in the Treatment of Diabetes Mellitus

BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy, 2008-01, Vol.22 (6), p.375-386

2008

Volltextzugriff (PDF)

Éléments stimulants et freins pour la titration optimale de l’insuline basale (IB) : résultats d’une enquête quantitative

Diabetes & metabolism, 2017-03, Vol.43 (2), p.A65

2017

Volltextzugriff (PDF)

CA-044 - Éléments stimulants et freins pour la titration optimale de l’insuline basale (IB) : résultats d’une enquête quantitative

Diabetes & metabolism, 2017-03, Vol.43 (2), p.A65-A65

2017

Volltextzugriff (PDF)

Comparative Assessment of Lixisenatide, Exenatide, and Liraglutide Pen Devices: A Pilot User-Based Study

Journal of diabetes science and technology, 2014-01, Vol.8 (1), p.123-131

2014

Volltextzugriff (PDF)

Correction to: InRange: Comparison of the Second-Generation Basal Insulin Analogues Glargine 300 U/mL and Degludec 100 U/mL in Persons with Type 1 Diabetes Using Continuous Glucose Monitoring—Study Design

Diabetes therapy, 2020-08, Vol.11 (8), p.1907-1908

2020

Volltextzugriff (PDF)

Correction to: InRange: Comparison of the Second-Generation Basal Insulin Analogues Glargine 300 U/mL and Degludec 100 U/mL in Persons with Type 1 Diabetes Using Continuous Glucose Monitoring—Study Design

Diabetes therapy, 2020-05, Vol.11 (7), p.1607-1608

2020

Volltextzugriff (PDF)

131 - Communication Between Healthcare Professionals and Patients on Basal Insulin Titration: Results of a Quantitative Survey

Canadian journal of diabetes, 2016-10, Vol.40 (5), p.S48-S48

2016

Volltextzugriff (PDF)

Communication Between Healthcare Professionals and Patients on Basal Insulin Titration: Results of a Quantitative Survey

Canadian journal of diabetes, 2016-10, Vol.40 (5), p.S48-S48

2016

Volltextzugriff (PDF)

Higher proinflammatory cytokine production and spontaneous activation in some type 1 and type 2 diabetic subjects

Clinical immunology (Orlando, Fla.), 2014-11, Vol.155 (1), p.27-29, Article 27

2014

Volltextzugriff (PDF)

Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus

Core evidence, 2010-01, Vol.5, p.23-37

2010

Volltextzugriff (PDF)

Burden of Cardiovascular Disease in Adult Patients with Type 1 Diabetes in the US

PharmacoEconomics - open, 2020-09, Vol.4 (3), p.519-528

2020

Volltextzugriff (PDF)

1 – 25 von 63

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(47)
Mit Volltextzugriff
(58)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(31)
Life Sciences & Biomedicine
(28)
Humans
(27)
Diabetes
(23)
Endocrinology & Metabolism
(15)
Male
(15)
Middle Aged
(15)
Female
(14)
Aged
(11)
Diabetes Mellitus, Type 2 - Drug Therapy
(11)
Adult
(8)
Biological And Medical Sciences
(8)
Diabetes Mellitus
(8)
Hypoglycemia
(8)
Insulin
(8)
Medical Sciences
(8)
Diabetes Mellitus, Type 2 - Blood
(7)
Hypoglycemic Agents - Administration & Dosage
(7)
Immunology
(7)
Original
(7)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Continuous glucose monitoring‐based time‐in‐range using insulin glargine 300 units/ml versus insulin degludec 100 units/ml in type 1 diabetes: The head‐to‐head randomized controlled InRange trial

AUTONOMY: The First Randomized Trial Comparing Two Patient-Driven Approaches to Initiate and Titrate Prandial Insulin Lispro in Type 2 Diabetes

Response to comment on Edelman et al. AUTONOMY: the first randomized trial comparing two patient-driven approaches to initiate and titrate prandial insulin lispro in type 2 diabetes. Diabetes Care 2014;37:2132-2140

CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes

Double-Blind, Placebo-Controlled Trial Assessing Pramlintide Treatment in the Setting of Intensive Insulin Therapy in Type 1 Diabetes

Insights into optimal basal insulin titration in type 2 diabetes: Results of a quantitative survey

Temporal intra-individual variation of immunological biomarkers in type 1 diabetes patients: implications for future use in cross-sectional assessment

Reference Guide for Integrating Continuous Glucose Monitoring Into Clinical Practice

Detection of Hypoglycemia With the GlucoWatch Biographer

Inadequate Insurance Coverage for Overweight/Obesity Management

C ontinuous glucose monitoring‐based time‐in‐range using insulin glargine 300 units/ ml versus insulin degludec 100 units/ ml in type 1 diabetes: The head‐to‐head randomized controlled InRange trial

Effects of Vitamin E on susceptibility of low-density lipoprotein and low-density lipoprotein subfractions to oxidation and on protein glycation in NIDDM

CD8 T-cell reactivity to islet antigens is unique to type 1 while CD4 T-cell reactivity exists in both type 1 and type 2 diabetes

InRange: Comparison of the Second-Generation Basal Insulin Analogues Glargine 300 U/mL and Degludec 100 U/mL in Persons with Type 1 Diabetes Using Continuous Glucose Monitoring—Study Design

Pramlintide in the Treatment of Diabetes Mellitus

Éléments stimulants et freins pour la titration optimale de l’insuline basale (IB) : résultats d’une enquête quantitative

CA-044 - Éléments stimulants et freins pour la titration optimale de l’insuline basale (IB) : résultats d’une enquête quantitative

Comparative Assessment of Lixisenatide, Exenatide, and Liraglutide Pen Devices: A Pilot User-Based Study

Correction to: InRange: Comparison of the Second-Generation Basal Insulin Analogues Glargine 300 U/mL and Degludec 100 U/mL in Persons with Type 1 Diabetes Using Continuous Glucose Monitoring—Study Design

Correction to: InRange: Comparison of the Second-Generation Basal Insulin Analogues Glargine 300 U/mL and Degludec 100 U/mL in Persons with Type 1 Diabetes Using Continuous Glucose Monitoring—Study Design

131 - Communication Between Healthcare Professionals and Patients on Basal Insulin Titration: Results of a Quantitative Survey

Communication Between Healthcare Professionals and Patients on Basal Insulin Titration: Results of a Quantitative Survey

Higher proinflammatory cytokine production and spontaneous activation in some type 1 and type 2 diabetic subjects

Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus

Burden of Cardiovascular Disease in Adult Patients with Type 1 Diabetes in the US

Suchergebnisse filtern